

	Name of the Issue: Go Digit General			
1	Type of Issue	Initial Public 0		
2	Issue Size (Rs. Mn)	26146.	.46*	
	*Source: Prospectus dated May 17, 20			
3	Grade of issue along with name of t			
	Name N			
	Grade N	A		
4	Subscription Level (Number of	10).03*	
	times)			
	*The above figure is after removing m			
	*Source: Final post issue report dated	May 27, 2024		
5	QIB Holding (as a %age of Outstand	ling Capital) as disclosed to the stock	exchanges	
	Particulars		%	
	(i) On Allotment**		19.09%	
	(ii) at the end of the 1st Quarter immed	diately after the listing	21.32%	
	of the issue (June 30, 2024) *		21.0270	
	(iii) at the end of 1st FY (March 31, 202	25)*	Not Available	
	(iv) at the end of 2nd FY (March 31, 20	026) *	Not Available	
	(v) at the end of 3rd FY (March 31, 202	27) *	Not Available	
	**Reporting with the BSE. Represents	holding of Institutions category		
	* QIB Holding not disclosed as reporti	ng for relevant period has not been comp	oleted.	
6	Financials of the issuer			
0			2nd FY (March	3rd FY (March
	Parameters	1st FY (March 31,2025)*	31,2026)*	31,2027)*
	Income from operations	Not Available	Not Available	Not Available
	Net Profit/(Loss) for the period	Not Available	Not Available	Not Available
	Paid-up equity share capital	Not Available	Not Available	Not Available
	Reserves excluding revaluation reserves	Not Available	Not Available	Not Available
	* Financials not available as reporting	for the relevant years has not been com	pleted.	
7	Trading Status			
	The equity shares of Mankind Pharma	Limited are listed on both the BSE Limit	ed ("BSE") and the Natior	nal Stock Exchange
	("NSE") (and together with BSE the "S		. ,	0
	· · · · ·	- <i>i</i>		

The equity shares have not been suspended or delisted.

Particulars	Status
(i) at the end of 1st FY (March 31, 2025)*	Not Available
(ii) at the end of 2nd FY (March 31, 2026)*	Not Available
(iii) at the end of 3rd FY (March 31, 2027)*	Not Available

* Trading status not disclosed as the relevant fiscal years have not been completed.



8	Change in Directors of Issuer from the disclosures in the offer document				
	Particulars	Name of Director	Appointed / Resigned		
	(i) at the end of 1st FY (March 31, 2025)*	Not Available	Not Applicable		
	(ii) at the end of 2nd FY (March 31, 2026)*	Not Available	Not Available		
	(iii) at the end of 3rd FY (March 31, 2027)*	Not Available	Not Available		
	* Changes in Directors of Issuer not updated as the relev	ant financial years have not	been completed		
	Status of implementation of project/ commencement	of commercial production			
	(i) as disclosed in the offer document	N	lot applicable		
	(ii) Actual implementation	Ν	lot applicable		
	(iii) Reasons for delay in implementation, if any	Ν	lot applicable		

10 Status of utilization of issue proceeds

(i) as disclosed in the offer document		In Million
Particulars	Amount proposed to be financed from Net Proceeds	Estimated Utilisation of Net Proceeds in Fiscal 2025
Investments to maintain solvency ratio	10647.00	10647.00
General Corporate Purposes	-	-
Total Proceeds Source: Prospectus dated May 17, 2024	10647.00	10647.00

(ii) Actual implementation Particulars	Amount proposed to be financed from Net Proceeds	Actual Utilisation of Net Proceeds	Unutilised Net Proceeds
Investments to maintain solvency ratio	10647.00	0.00	10647.00
General corporate purposes	-	-	-
Total Proceeds	10647.00	0.00	10647.00
(iii) Reasons for delay in implementation, if any		Not applicable	



11 Comments of monitoring agency, if applicable

There has been no deviation. The nil statement under regulation 32 of SEBI Listing Regulation in this regard has been reviewed by Audit Committee at its meeting held on 25th July 2024.

Not applicable

Not applicable

(i) Comments on use of funds

(ii) Comments on deviations, if any, in the use of proceeds of the Issue from the objects stated in the Offer document(iii) Any other reservations expressed by the monitoring agency about the end use of funds

12	Pricing Data						
	Designated Stock Exchange	NSE					
	Issue Price (Rs.)	272.00					
	Listing Date	23-May-24	22-Jun-24		_		
	Price parameters	At close of listing day- 23-05-2024	Close of 30th calendar day	Close of 90th calendar day from	As at the end of the 1nd FY after the listing of the iss (31st March,2025) ⁽¹⁾		-
			from listing day	listing day(1)	Closing price	High	Low
	Market Price	306.00	334.10	Not Available	Not Available	Not Available	Not Available
	Nifty 50*	22,967.65	23,501.10	Not Available	Not Available	Not Available	Not Available

Price parameters	As at the end of the 2nd FY after t	he listing of the issue (31	st March,2026) ⁽¹⁾	As at the end of t	the 3rd FY after th (31st March,2027	e listing of the issue ′) ⁽¹⁾
	Closing price	High	Low	Closing price	High	Low
Market Price	Not Available	Not Available	Not Available	Not Available	Not Available	Not Available
Nifty 50*	Not Available	Not Available	Not Available	Not Available	Not Available	Not Available

* Being index of NSE, the designated stock exchange

(1) The pricing data is not disclosed as the relevant fiscal years have not been completed

(2) Closing prices have been considered. In case of the date falling on holiday, previous working day has been considered



13 Basis for Issue Price

Accounting ratio		Face Value per share (Rs.)	As disclosed in offer document*	At the end of 1st FY (March 31,2025)**	At the end of 1st FY (March 31,2026)**	At the end of 1st FY (March 31,2027)**
	Company					
	Consolidated	10	0.40	Not Available	Not Available	Not Available
	Peer Group:					
EPS (Diluted)	New India Assurance Company Limited	5	6.36			
	Star Health and Allied Insurance Company	10	10.41	Not Available	Not Available	Not Available
	ICICI Lombard General Insurance Company Ltd	10	35.16	Not Available	Not Available	ot Available Not Availab ot Available Not Availab
	Industry Avg		17.31	Not Available	Not Available	Not Available
	Company					
	Consolidated		NA	Not Available	Not Available	Not Available
	Peer Group:					
P/E	New India Assurance Company Limited		38.47	Not Available	Not Available	Not Available
	Star Health and Allied Insurance Company Limited		53.79	Not Available	Not Available	Not Available
	ICICI Lombard General Insurance Company		48.14	Not Available	Not Available	Not Available
	Industry Avg		46.80	Not Available	Not Available	Not Available
	Company					
	Consolidated		1.53%	Not Available	Not Available	Not Available
	Peer Group:					
RoNW	New India Assurance Company Limited		5.13%	Not Available	Not Available	Not Available
	Star Health and Allied Insurance Company		11.39%	Not Available	Not Available	Not Available
	ICICI Lombard General Insurance Company Ltd		16.64%	Not Available	Not Available	Not Available
	Industry Avg		11.05%	Not Available	Not Available	Not Available



	Company				
	Consolidated	26.61	Not Available	Not Available	Not Available
	Peer Group:				
NAV per share	New India Assurance Company Limited	125.64	Not Available	Not Available	Not Available
	Star Health and Allied Insurance Company Limited	93.35	Not Available	Not Available	Not Available
	ICICI Lombard General Insurance Company Ltd	211.60	Not Available	Not Available	Not Available
	Industry Avg	143.53	Not Available	Not Available	Not Available

Notes

* Sourced from Prospectus dated May 17, 2024.

**Not available as the relevant fiscal years have not been completed / information not disclosed

14 Any other material information

Particulars	Date	Remarks
For further updates and information, please refer stock exchange websites i.e. www.bseindia.com and www.nseindia.com		
Source: Stock Exchange filings		

Source: Stock Exchange filings